Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2020

View Archived Issues

Heparan sulfate DAMPens acetaminophen toxicity

IL-4Ra R576 polymorphism linked to atopic dermatitis severity

Fibroblast PIK3Cdelta modulates triple-negative breast cancer progression

Onivyde i.v. infusion approved in Japan

HMGN1 enhances stem cell-ness and cooperates with leukemia oncogenes in malignant transformation

FDA approves Zeposia as oral treatment for relapsing forms of multiple sclerosis

First patient dosed in EVICTION study of ICT-01

Oncopeptides announces final data from pivotal HORIZON study of melflufen

Positive interim analysis data presented from phase III OVAL study

CYSLTR2 variant associated with aspirin-induced acute urticaria/angioedema

Periostin as biomarker in asthma patients with diabetes treated with GLP-1R agonists

First-in-human long-term data presented for hAECs in extremely preterm infants

Femtogenix patents new antibacterials

Roche presents gamma-secretase inhibitors

Assembly Biosciences discloses compounds for HBV infection

Merck KGaA identifies new ATR kinase inhibitors

Risen (Suzhou) Pharma Tech synthesizes new CD73 inhibitors

Setting "evolutionary traps" can lure cancer cells into an ambush

Researchers develop murine model of eosinophilic esophagitis

Nobelpharma obtains approval in Japan for Melatobel

Inovio reports interim phase II data on VGX-3100 in HPV-associated anal dysplasia

Ailamide approved in Japan for glaucoma and ocular hypertension

New: BioWorld Science now includes product links to Cortellis Drug Discovery Intelligence

Otsuka reports promising data from Japanese phase III studies of difamilast for atopic dermatitis

Arbutus releases preliminary data from first-in-human study of AB-729 for HBV

Roche opens phase III trial of tiragolumab with atezolizumab in treatment-naive advanced NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...